Perlmutter Cancer Center Support Groups & Counseling | NYU Langone Health
At Perlmutter Cancer Center, we offer support groups and counseling for patients and caregivers during treatment for cancer.
Perlmutter Center for Women’s Imaging | NYU Langone Health
NYU Langone’s Perlmutter Center for Women’s Imaging offers mammography, breast ultrasound, and bone density testing.
Personalized Dietary Management in Type 2 Diabetes Lay title: The DIAbetes TELEmedicine MEDiterranean Diet Study (DIATELEMED)
Limiting blood sugar peaks following meals is an important treatment goal in the management of type 2 diabetes, but evidence is mixed regarding the best dietary approach to achieve this goal. One-size-fits-all dietary recommendations may fail to limit blood sugar peaks because individuals differ greatly in their blood sugar responses to the very same foods. In this study we will compare to an education control group, two Mediterranean-type diabetic diets, one that has been standardized and one that has been personalized using a gut microbiome-based algorithm to limit blood sugar peaks following meal
PERSPIRE: A pilot study of Pro-rEsolving and pRo-inflammatory reSPonses to acute exhaustIve exeRcisE in healthy individuals
Observational, intervention study of the effects of acute, exhaustive exercise on pro-resolving and pro-inflammatory responses in healthy, trained and untrained adults. The study requires one visit (a second, optional visit may occur). At the visit, subjects will have blood drawn at several time points and also perform an exhaustive bout of treadmill exercise. Differences in specialized pro-resolving lipid mediators (SPMs) and other measures of inflammation and resolution over time will be characterized.
PET/CT Scans | NYU Langone Health
NYU Langone offers PET/CT scans to diagnose illness, evaluate treatments, and assess the recurrence of many conditions, including cancer.
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors
Although recent advances have been made in the treatment of some solid tumors, there remains a high unmet need for patients who have malignancies that have relapsed or are refractory to chemotherapy, including targeted therapies, immunotherapy, or radiotherapy. OV therapy utilizes engineered viral particles (VPs) to directly lyse tumor cells and increase the amount of tumor antigen able to be processed and presented to the immune system. Thus far, only one approved OV therapy exists in the US. Imlygic® (talimogene laherparepvec) (Imlygic® USPI) is a herpes simplex virus 1 coding for granulocyte macrophage colony-stimulating factor (GM-CSF) and is approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Imlygic® has not been shown to have an effect on visceral metastases. In a recent phase 3 randomized, double-blind trial, MASTERKEY-265, Imlygic and pembrolizumab did not show increased progression free survival or overall survival over placebo and pembrolizumab for patients with melanoma. No OV options exist for other solid tumors, including lung, breast, colon, genitourinary, and central nervous system, or as IV administration as systemic therapy.Despite these data, OV therapy represents a unique type of therapy that combines self-amplification and self-propagation, as well as lytic and immunostimulatory properties against cancer. Very little progress has been made in the treatment of solid tumor where chemotherapy and checkpoint inhibitors are the mainstay of treatment for metastatic disease. These are limited by eventual resistance and toxicity. Viral agents may represent an alternative approach to target tumor specific cells while sparing normal cells. OVs remain a promising approach as virus can infect tumor cells and selectively replicate in them, leading to cancer cell lysis, and release of new viruses, which can infect additional tumor cells. Furthermore, virus could spread to distantICVB-1042Clinical Study Protocol 1042-CLN01 V2.0Confidential 20 IconOvir Biotumor metastasis and induce a systemic immune system to react against the tumor. When the tumor is eradicated, the virus is unable to further replicate and it thus cannot exist.Study 1042-CLN01 is a Phase 1 first-in-human (FIH) dose escalation and expansion study to assess safety and tolerability of IV administration of ICVB-1042 in patients with advanced or metastatic solid tumors that have relapsed and/or are refractory to at least one prior line of standard treatment, or the patient is not able to tolerate available therapies, or such therapies are contraindicated. Patients who have refused standard treatments may be eligible for this study after discussion with the sponsor/medical monitor.
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
The tumor-associated antigens mesothelin (MSLN) and cadherin-3 (CDH3) areco-expressed in multiple tumor types, with minimal overlap observed in normal tissues.AMG 305 is a first dual-targeting BiTE (dBiTE™) molecule (CDH3-MSLN half-life extended [HLE] dBiTE™ AND dual targeting, HLE BiTE molecule) that targets the antigens P-cadherin (CDH3) and MSLN as well as CD3 on T-cells. AMG 305 is designed to increase the therapeutic index in solid tumors by preferentially targeting tumor cells that co-express CDH3 and MSLN over normal cells that express only 1 of these targets.
Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, andPreliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors
To evaluate the safety and tolerability of RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumorsTo estimate the MTD and/or RP2DS for RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumors